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Abstract
Myeloid and plasmacytoid dendritic cells (mDCs, pDC) are crucial to the immune system, detecting
microorganisms and linking the innate and adaptive immunity. pDC are present in small quantities
in tissues that are in contact with the external environment; mainly the skin, the inner lining of the
nose, lungs, stomach and intestines. They produce large amounts of IFN-α after stimulation and are
pivotal for the induction of antiviral responses. Chronic obstructive pulmonary disease (COPD)
patients are known to be more susceptible to viral infections. We have demonstrated that
exposure of mDC to cigarette smoke extract (CSE) leads to the release of chemokines, however,
not much is known about the role of pDC in COPD. In this study, we addressed several key
questions with respect to the mechanism of action of CSE on human pDC in an in vitro model.
Human pDCs were isolated from normal healthy volunteers and subjected to fresh CSE and the
levels of IL-8, TNF-α, IP-10, IL-6, IL-1, IL-12 and IL-10 and IFN-α were studied by both ELISA and
real time PCR methods. We observed that CSE augmented the production of IL-8 and suppressed
the release of TNF-α, IL-6 and IFN-α. Moreover, CSE suppressed PI3K/Akt signalling in pDC. In
conclusion, our data indicate that CSE has both the potential to diminish anti-viral immunity by
downregulating the release of IFN-α and other pro-inflammatory cytokines while, at the same time,
augmenting the pathogenesis of COPD via an IL-8 induced recruitment of neutrophils.
Introduction
Cigarette smoking is the most important risk factor for
chronic obstructive pulmonary disease (COPD) and is
expected to emerge as the third most common cause of
death by 2020 [1,2]. Cigarette smoke induces both the
release of chemokines from airway epithelial cells and
alveolar macrophages resulting in the recruitment of neu-
trophils, monocytes, CD8+ and CD4+ cells into the lungs
as well the release of excessive amounts of proteases from
macrophages and neutrophils. Degradation of extracellu-
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lar matrix components within alveolar walls by these pro-
teases leads to the development of lung emphysema, the
main characteristic of the COPD [1]. Despite a clear role
for macrophages and neutrophils in the pathogenesis of
emphysema, the contribution of dendritic cells (DCs)
during COPD is not well documented.
In humans and mice, several subtypes of DC have been
described. Generally, DCs can be divided into conven-
tional DC (cDC or "myeloid" mDC) and plasmacytoid
DC (pDC) [3-6]. While mDC are located mainly within
tissues, human pDC represent a rare leukocyte subset that
can be found in the peripheral blood and secondary lym-
phoid organs and are characterized by their plasma cell-
like morphology and unique surface receptor phenotype
[7]. Similar to mDC, pDCs sense pathogens via a reper-
toire of primary pattern recognition receptors (PRRs)
including Toll-like receptors (TLRs). Unlike mDCs, how-
ever, pDCs express TLR9, which recognizes viral double-
stranded microbial DNA [4]. This characteristic makes
pDC a pivotal cell in innate antiviral immunity by allow-
ing them to rapidly secrete abundant amounts of type I
IFNs after exposure to various DNA and RNA viruses [7]
Current studies of the suppressive effects of cigarette
smoke components on leukocyte function have shown
some effects on mDCs. For example, it has been reported
that exposure of human mDCs to CSE impairs the capac-
ity of DCs to induce T-cell proliferation and Th1 differen-
tiation while increasing Th2 differentiation, IL-10
production, and prostaglandin E2 release [8]. It is
unknown which components of CSE are responsible for
these effects, however, it is unlikely that these effects are
mediated solely by nicotine because CSE is a mixture of
thousands of compounds in which nicotine is present
only in relatively low concentrations. In our study, we
extended our CSE investigation to human pDC and exam-
ined the pDC chemokines, IL-8 and IP-10 as agents for
attracting inflammatory cells [9]. The cytokines, TNF-α,
IL-6, IL-1, IL-12 and IL-10, were also studied for their
involvement in lymphocyte generation, local inflamma-
tory responses, vasodilatation and damage of airway tis-
sue [9].
Materials and methods
Reagents
CpG-A (ODN 2216) was purchased from InvivoGen
(Toulouse, France), and CpG-C from HyCult Biotechnol-
ogy (Uden, the Netherlands). RPMI 1640 and FCS were
obtained from Gibco-BRL Life Technologies (Breda, Neth-
erlands). LY294002, as PI3-K α inhibitor was purchased
from Calbiochem (VWR International B.V. Amsterdam,
The Netherlands).
Preparation of CSE
Cigarette smoke extract (CSE) was prepared as described
before[10]. CSE was generated by the burning of commer-
cially available Lucky Strike cigarettes without filter (Brit-
ish-American Tobacco, Groningen, The Netherlands),
using the TE-10z smoking machine (Teague Enterprises,
Davis, CA), which is programmed to smoke cigarettes
according to the Federal Trade Commission protocol (35-
ml puff volume drawn for 2 s, once per minute [11].
Briefly, this machine was used to direct main and side
stream smoke from one cigarette through 5 ml PBS. Here-
after, absorbance was measured spectrophotometrically
and the buffer was standardized to a standard curve of
CSE concentration against absorbance at 320 nm. The pH
of the resultant extract was titrated to pH 7.4, and diluted
with medium. This solution is considered to be 100%
CSM. Solutions ranging from 0.75% to 1.5% were used in
the present study following preliminary experiments,
which indicated that these were nontoxic concentrations
(viability ≥ 96%).
Isolation of human plasmacytoid dendritic cells (pDCs)
Trisodium citrate (0.4% (w/v) (pH 7.4)) anti-coagulated
fresh blood was obtained from healthy volunteers at the
donor service of the University Medical Center (Utrecht,
the Netherlands). Peripheral blood mononuclear cells
(PBMC) were collected after centrifugation over isotonic
Ficoll (Pharmacia, Uppsala, Sweden), and plasmacytoid
dendritic cells were isolated from PBMCs by Diamond
Plasmacytoid Dendritic Cell Isolation Kit by using CD304
MicroBeads (Magnetic cell sorting/MACS/; Miltenyi Bio-
tech, Utrecht, the Netherlands). The purity was higher
than 95% assessed by the flow cytometric analysis of
CD123 expression (BD Biosciences, San Jose, CA, USA) in
a pilot study. Cells were cultured in RPMI 1640 supple-
mented with 10% FCS.
Activation of pDCs
Human pDCs were cultured with various stimuli at 37°C
under a humidified atmosphere with 5% CO2 in a V-bot-
tom 96-well plate for 5 h for real-time PCR analysis, 8 h
for assessing cytokine production (106/ml) and 90 min in
the p-Akt assay (80,000 cells/well). Cells were stimulated
with CSE (1.5%) alone and, in order to test the effect of
CSE on activated pDCs, cells were simultaneously acti-
vated with TLR9 (2 μM CpG-A or 1 μM CpG-C) agonists.
For the real time PCR analysis, cells were spun for 5 min
at 1200 rpm at 4°C, washed once in cold PBS, the reverse
transcription protocol was immediately, and cDNA was
stored at -20°C till the real-time PCR reaction. For
cytokine and chemokine measurements, supernatants
were collected by spinning for 5 min at 1200 rpm at 4°C
and stored at -20°C till analysis.Respiratory Research 2009, 10:47 http://respiratory-research.com/content/10/1/47
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Assessing cell viability
Cell viability was assessed on fresh cells at the end of each
treatment with propidium idodide (PI, Sigma-Alderich)
staining. 10,000 events were counted in the cell gate by
FACS (FACS Calibur, BD Bioscience, Becton Dickinson).
Measurement of cytokines
IFN-α was measured by sandwich ELISA (PBL Biomedical
Laboratories, Piscataway, NY, USA) while IL-6, IL-8, TNF-
α, IL-10 and IL-1β concentrations were measured with the
Cytometric Bead Array Human Inflammation Kit (BD Bio-
science) on a flow cytometer (FACS Calibur).
Real-time PCR
cDNA synthesis and Q-PCR were performed using the
Superscript III Platinum CellsDirect Two-step qRT-PCR
Kit with SYBR Green (Invitrogen, Toulouse, France)
according to the manufacturer's instructions. Briefly, after
incubation cells were washed once and resuspended in 10
μl cold PBS and 2 μl (i.e. 10,000 cells) was lysed in 11 μl
lysis buffer. Then the cell lysate was treated with DNase I
to degrade any contaminating DNA. During first strand
cDNA synthesis, the reaction mix contained 2 μl RT
Enzyme Mix (100 units/μl SuperScript III RT, 20 units/μl
RNaseOUT Recombinant Ribonuclease Inhibitor), 20 μl
2× RT Reaction mix (2.5 μM oligo(dT)20, 2.5 ng/μl ran-
dom hexamer, 10 mM MgCl2 and dNTPs) in 40 μl reac-
tion volume. The reaction was allowed to proceed
(incubation: 25°C, 10 min, RT: 50°C, 20 min; PCT-100
Programmable Thermal Controller, MJ Research Inc.,
Watertown, MA, USA), and then it was halted by heating
the samples to 85°C for 5 min. Afterwards 1 μl of RNase
H (2 U/μl) was added to each well and incubated at 37°C
for 20 min. The reaction was chilled on ice.
Primers for Q-PCR were synthesized by Invitrogen and
were as follows: β2-microglobulin (forward, 5'-CTCCGT-
GGCCTTAGCTGTG-3'; reverse, 5'-TTTGGAGTACGCTGG
ATAGCCT-3'), IL-8 (forward 5'-CTGGCCGTGGC TCT CT
TG-3'; reverse 5'-CCTTGGCAAAACTGCACCTT-3'), IF N-α
(forward 5'-GGTGCTCAGCTGCAAGTCAA-3'; reverse, 5'-
GCTACCCAGGCTGTGGGTT-3'). The Q-PCR reactions
were performed in 25 μl reaction volume with 4 μl cDNA,
12.5 μl Platinum SYBR Green qPCR SuperMix-UDG and
200 nM sense and antisense primers. Cycling conditions
were 50°C for 2 minutes, 95°C for 2 minutes and then 50
cycles of 95°C for 15 seconds and 60°C for 30 seconds
(ABI PRISM 7000 Sequence Detection System, Applied
Biosystems, Foster City, CA, USA). PCR amplicon effi-
ciency for primers was calculated using serially diluted
pooled cDNA. The relative level of mRNA expression of a
specific gene was calculated based on ΔΔCT method, and
normalized to mRNA level for the housekeeping gene β2-
microglobulin.
Measurement of Nitric Oxide
As an indicator of NO production, nitrite concentration
was measured in the supernatants of samples. Equal vol-
umes of the sample and Griess reagent (1% sulphanila-
mide in 5% phosphoric acid and 0.1% N-[1-naphthyl]-
ethylendiamine) were mixed and the absorbance was read
at 450 nm as described before [12]. The amount of nitrite
was obtained by an extrapolation from a standard curve
with sodium nitrite and was expressed as μmol/mg tissue.
Detection of p-Akt by flow cytometry
The method was adopted from Guiducci et al [13]. 8 × 104
pDCs were pretreated with LY294002 (10 μM) and then
stimulated with 1 μM CpG-C, CSE or the combination of
the two stimulants for 90 min in a V-bottom 96-well
plate. Then cells were fixed with 4% paraformaldehyde for
15 min at 37°C. Cells were then washed with incubation
buffer (1% FCS in PBS), and permeabilized with 90% ice-
cold methanol for 30 min on ice. After washing cells were
blocked for 10 min in incubation buffer, and then stained
with Alexa Fluor 647 anti-human AKT (pS473) or with
Alexa 647 isotype control antibodies according to the
manufacturer's instructions. All antibodies were pur-
chased from Cell Signaling Technologies (Bioke, Leiden,
the Netherlands).
Statistical analysis
For assessing the effect of CSE on IFN-α production
induced by different stimulants, unpaired t-test was used.
In other comparisons, one-way ANOVA was applied with
the Newman-Keuls Multiple Comparison post-hoc test
(GraphPad Prism 4.0; GraphPad Software Inc., San Diego,
California, USA). Data are expressed as mean ± SEM, p <
0.05 was considered to be significant.
Results
CSE induced IL-8 release is enhanced by TLR9 stimulation
The effect of CSE on IL-8 production by pDCs was studied.
Cells were exposed for 5 h and 8 h to different concentra-
tions of CSE (0.75–6%). The level of IL-8 was determined
by Q-PCR and ELISA, respectively. Incubation of pDC
with CSE dose-dependently induced release of IL-8 (Fig.
1A) with an optimum at 1.5% CSE. At high concentration
(6%), the release of IL-8 was declined which is likely due
to the cytotoxicity of CSE at high concentrations as
detected by PI staining (Fig. 1B). As shown in Fig. 1, stim-
ulation of cells with CpG-A (2 μM) induces up-regulation
of the mRNA and protein release of IL-8 and addition of
CSE (1.5%) with CpG-A potentiates the mRNA expression
and protein releases of IL-8 (Fig. 1C and 1D). No signifi-
cant cytotoxicity of cells were seen either with CpG-A
alone or in combination with CSE (1.5%) as detected by
PI staining (Fig. 1B).Respiratory Research 2009, 10:47 http://respiratory-research.com/content/10/1/47
Page 4 of 9
(page number not for citation purposes)
TLR9 induced cytokines release is inhibited by CSE
We studied the effects of CSE on cytokine release of
human pDC. TLR9 stimulation by CpG-A resulted in the
production of TNF-α and IL-6 (Fig. 2A and 2B). In con-
trast, CSE exposure of CpG-A-activated pDC resulted in a
profound reduction in TNF-α and IL-6 production when
compared to pDC exposed only to CpG-A (Fig. 2A and
2B). CSE did not have an effect on IL-10, IL-1β, IP-10 and
IL-12 release by pDC (data not shown).
CSE inhibited TLR-9-induced IFN-α at mRNA and protein 
levels of pDC
To test whether CSE modulates IFN-α mRNA expression
and protein release, pDCs were exposed to CSE alone or
in combination with TLR9 agonist for 5 h and 8 h for
determination mRNA and protein levels, respectively.
CpG-A has been shown to rapidly induced high levels of
IFN-α from human pDCs [14]. CSE did not up-regulate
mRNA expression and protein release of IFN-α and sup-
pressed the mRNA and protein levels of IFN-α in CpG-A
activated cells (Fig. 3A and 3B).
CSE suppressed TLR9-induced IFN-α induction in pDC via 
attenuating the PI3K/Akt pathway
Recently, it has been demonstrated that CpG ODN
induced production of type I IFN-α by pDC, induced is
highly dependent on the activity of phosphatidylinositol-
3 kinase (PI3K) [13]. We measured phosphorylated Akt
(p-Akt), a downstream molecules of PI3K signaling [15].
CpG-C as a positive control, induced phosphorylation of
Akt after 90 min compared to control cells (Fig. 4A and
4B), Ly 294002 treatment (as a specific inhibitor for PI3K
pathway) suppressed the phosphorylation of Akt (Fig 4C).
CSE did not induce phosphorylation of Akt (Fig. 4D) by
CSE induces IL-8 release and potentiates TLR-mediated IL-8 release Figure 1
CSE induces IL-8 release and potentiates TLR-mediated IL-8 release. pDCs (106 cells/ml) were stimulated with vari-
ous concentrations of CSE (0.75–6%) for 8 h and amounts of IL-8 release was determined by supernatants of samples by ELISA 
(A). The viability of cells were determined after treatment with CSE at various concentration, CpG-A (2 μM) or in combination 
CSE (1.5%) and CpG-A (2 μM) by staining of cells with propidium idodide (PI) for 5 min. Cells were then analyzed by flow 
cytometry for a cell count of 10000. Data are presented as means ± SD from triplicates and three independent experiments 
(B). pDC (106 cells/ml) were stimulated with CSE (1.5%), CpG-A (2 μM) or in combination for 5 and 8 h and amounts of IL-8 at 
mRNA levels (C) and protein levels (D) was determined by total RNA and supernatants of samples by real time PCR and 
ELISA, respectively. Data presented mean ± SEM of 3 independent experiments; *p < 0.05, **p < 0.01).Respiratory Research 2009, 10:47 http://respiratory-research.com/content/10/1/47
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itself, but suppressed the phosphorylation of Akt induced
by CpG-C (Fig. 4E).
Discussion
COPD is a major cause of morbidity and mortality world-
wide. There is increasing evidence that implicates viral
infections as a major risk factor for exacerbations of
COPD [16,17]. Dendritic cells are the main sentinels of
the immune systems. They are capable of detecting virus-
associated nucleic acids through PRRs such as TLRs and
cytosolic viral sensors. Viral nucleic acids activate DCs to
produce a variety of soluble factors including proinflam-
matory cytokines and type I interferons (IFNs). pDCs are
particularly skilled in virus detection and have been
shown to produce high levels of IFN-α/β and TNF-α in
response to a wide variety of viruses in both humans and
mice [3]. Given that cigarette smoking is associated with
an increased risk of infections, we hypothesized that ciga-
rette smoke may modulate the expression and release of
pDC-associated mediators. Therefore, we analyzed the
effect of CSE on pDC with an in vitro experimental model.
CSE induced the release of IL-8 and suppressed the TLR9-
ligand induced TNF-α, IL-6 and IFN-α production. More-
over, the suppressive effects of CSE were associated with
an attenuated phosphorylation of Akt. To our knowledge,
these data are the first that demonstrate modulatory
effects of CSE on pDC function.
Cigarette smoke contains an extraordinarily complex mix-
ture of chemicals [18]. As a result, identifying cigarette
smoke constituents responsible for certain biological
effects is a daunting task, leading some to favour a reduc-
tionist approach over the use of complete extracts from
cigarette smoke. Although CSE is arguably not fully repre-
sentative of "true" cigarette smoke exposure, it is impor-
tant to note that in vivo cells are not exposed to cigarette
smoke, but rather to cigarette smoke constituents that
have been solubilised into biological fluids such as the
epithelial and alveolar lining fluid in the lungs. In recog-
nition of these caveats, we used a number of parallel and
complimentary approaches to define the effect of soluble
cigarette smoke on different inflammatory cells [19-21].
Accumulating evidence supports that IL-8 is the main
chemokine in the recruitment of neutrophils into the air-
ways and lung of COPD patients [22,23]. We and others
have demonstrated that CSE can induce the release of IL-
8 (or CXCL-8) from human monocytes, mDC and murine
mast cells [10,20]. In the current study, CSE induced IL-8
release by pDC and, interestingly, this effect was more
pronounced after adding a TLR9 agonist. This finding has
also been reported in human mDC exposed to a combina-
tion of CSE and LPS (a TLR4 ligand) [8]. Thus, we can pos-
tulate that CXCL-8 production by pDC in response to CSE
may have a significant impact on the recruitment of pro-
inflammatory cells in to the airway. As stated earlier, CSE
did not induce the production of TNF-α, IL-6 and IL-10,
IL-1β (data not shown) and IFN-α production, but sup-
pressed the the ability of a TLR9 agonist (CpG-A and CpG-
C) to induce these cytokines. Suppressive effects of CSE on
cytokine production have been shown in other cell types
[24-27]. For example, CSE inhibits the release of TNF-α
but not IL-6 after stimulation with Poly I:C as TLR3 ligand
in PBMC [28].
The inhibition of IFN-α production by CSE has been ear-
lier demonstrated in experiments with human lung
fibroblast and epithelial cells [29]. Although the inhibi-
tion of IFN-α production could be a general effect of CSE,
it can also be speculated that CSE is having a critical effect
on pDC as this cell type produces high amounts of IFN-α.
Thus CSE may play an important role in the suppression
CSE suppresses TNF-α and IL-6 production induced by CpG-A of pDC Figure 2
CSE suppresses TNF-α and IL-6 production induced by CpG-A of pDC. pDCs (106 cells/ml) were stimulated with 
CSE (1.5%), CpG-A (2 μM) or the in combination for 8 h for protein levels (A and B). Cytokines concentration of cell superna-
tants were measured with cytometric bead array (mean ± SEM of 3 independent experiments; *p < 0.05, ***p < 0.001).Respiratory Research 2009, 10:47 http://respiratory-research.com/content/10/1/47
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of the antiviral cytokine production of smokers and
COPD patients. To further understand the effects of CSE
on the attenuation of IFN-α secretion, molecular biology
approaches were used. To date, only a few studies have
documented ways in which INF-α by pDC is regulated.
For example, IL-10 suppresses IFN-α secretion independ-
ently of TLR9 by pDC [30] and cross-linking surface com-
plexes of IgE/FcεRI or pre-treatment of pDC with TNF-α
reduces INF-α release in response to CpG-A via an auto-
crine loop of TNF-α [30] In the current study, we did not
find any release of TNF-α and IL-10 by CSE (data not
shown). Other studies have shown that CSE decreases the
expression of IFN-α regulatory factor-7 (IRF-7) transcripts
[29] and that exogenous nitric oxide (NO) inhibits IFN-α
production of pDC by downregulating IRF-7 expression
via a cGMP-dependent pathway [31]. In our study, we can
exclude the effects of NO since we did not find the pro-
duction of TNF-α and NO by CSE (data not shown).
Earlier studies have demonstrated that PI3K (Akt) plays a
critical role in production of IFN-α by human pDC and
that the downregulation of this pathway with pharmaco-
logic inhibitors abrogates the release of IFN-α [13,32].
Similarly, we have shown that CSE is also capable of atten-
uating Akt (down-stream molecules of PI3k) phosphor-
ylation leading to reductions in IFN-α production. Besides
controlling IFN-α expression, the PI3K pathway is also
involved in a variety of biological processes, including cell
CSE inhibits TLR-induced mRNA expression and protein production of IFN-α by pDC Figure 3
CSE inhibits TLR-induced mRNA expression and protein production of IFN-α by pDC. pDCs (106cells/ml) were 
stimulated with CpG-A (2 μM), CSE (1.5%) or in combination for 5 h, then lyzed, followed by RNA extraction and real time 
PCR analysis. IFN-α mRNA expression is normalized to housekeeping gene (β2-microglobulin) expression, and shown as fold 
induction over expression of non-stimulated control cells (A). pDCs (1 × 106/ml) were stimulated with CpG-A (2 μM), CSE 
(1.5%) or incombination and CSE (1.5%) for 8 h (B). IFN-α concentration of culture supernatants were determined by ELISA 
(mean ± SEM of 3 independent experiments; ***p < 0.001).Respiratory Research 2009, 10:47 http://respiratory-research.com/content/10/1/47
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survival and proliferation, B and T cell receptor signaling,
and the activation of G protein-coupled receptors, such as
chemokine receptors [33]. The PI3K pathway is also acti-
vated by various TLR ligands and can function as a posi-
tive or negative regulator of TLR responses depending on
the cell type and the TLR ligand used [34]. PI3K activation
is an important early step in the signaling pathway leading
to IRF-7 nuclear translocation and type I IFN-α produc-
tion after TLR 9 activation by pDCs that differentially reg-
ulate the IRF-7 and NF-κB signaling pathways [13].
pDCs, through their production of high levels of type I
IFN-α, play a critical role in the pathophysiology of vari-
ous autoimmune diseases, such as systemic lupus ery-
thematosus, psoriasis, or Sjögren's disease [35-37].
 However, our studies are purely in vitro and should be
verified by in vivo investigations before translating their
relevance to these diseases.
In conclusion, CSE induces both the release of IL-8 and
the suppression of TLR9 ligand-induced IFN-α and pro-
inflammatory cytokine production. Increased release of
IL-8 may lead to a magnified recruitment of neutrophils
into the lungs. On the other hand, suppression of IFN-α
may lead to impaired host defence thereby increasing the
risk of airway infections, a major cause of COPD exacerba-
tion. As downregulation of the PI3K pathway is likely
responsible for these effects, stimulators of the PI3K path-
way may have a protective effect in COPD patients and
lead to the development of new drugs to treat COPD.
CSE inhibits Akt activation induced by CpG-C by human pDCs Figure 4
CSE inhibits Akt activation induced by CpG-C by human pDCs. pDCs (106cells/ml) were cultured for 90 min (A) 
without stimulant as control, (B) stimulated with CpG-C (1 μM), (C) pretreatment for 30 with LY294002 (10 μM) and then 
stimulated with CpG-C (1 μM), (D) stimulated with CSE (1.5%) and (E) in combination CSE (1.5%) and CpG-C (1 μM). Follow-
ing fixation and permeabalization, cells were stained with Alexa Fluor 647 phospho anti-human Akt or Alexa 647 isotype con-
trol antibodies, as specified in the "Materials and methods". A representative of three independent experiments is shown. 3,000 
events were counted in the pDC gate.Respiratory Research 2009, 10:47 http://respiratory-research.com/content/10/1/47
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